Analysis of 367 Patients with Somatostatin-Positive Tumors after PRRT with 177Lu-DOTATATE
| Characteristic | All patients | Lung + GEP NET patients | Non-GEP NET patients* |
| Total number of patients | 367 | 274 | 93 |
| Number of PHD patients | 13 | 11 | 2 |
| Prevalence | 3.5% | 4.0% | 2.2% |
| Median latency period (mo) | 36 (range, 5–84) | 41 (range, 15–84) | 5.8 (range, 5–7) |
| Median follow-up time (mo) | 24 (range, 0–143) | 29 (range, 0–142) | 12 (range, 0–116) |
| Cumulative median BM dose (Gy) | |||
| Without PHD | 2.0 (range, 0.2–4.0) | 2.0 (range, 0.2–4.0) | 1.5 (range, 0.2–3.9) |
| With PHD | 1.5 (range, 1.0–2.0) | 1.76 (range, 1.0–2.0) | 1.2 (range, 1.0–1.5) |
| Expected number with MDS/leukemia | 4.4 | 3.0 | <1 |
| Cumulative follow-up (person-years) | 1,309 | 1,113 | |
| Relative risk | 1.9 (95% CI, 1.0–3.6) | 2.7 (95% CI, 0.7–10.0) | |
| Significant risk factors | Baseline WBC was significantly lower (P = 0.01) in 13 NET patients with PHD | None | NC |
| Subacute hematologic toxicity grade 3–4 during PRRT was marginally significantly (P = 0.053) different in patients with PHD | |||
| Remark | Including a non-GEP NET patient treated with 131I, resulting in BM failure, 5 mo after first PRRT cycle |
↵* Patients with non-GEP NET, for example, NET of unknown primary, thyroid carcinoma, or paraganglioma.
CI = confidence interval; NC = not calculated because of low statistical power.